CAR-T that targets other tumor-associated antigens such as B cell maturation antigen (BCMA) for multiple myeloma (MM)7,8, CD20 for lymphoma and chronic lymphocytic leukemia9 and CD12310 to target acute myeloid leukemia are showing promising results. Here, TNFRSF17 is linked to plasma cell myeloma.